FDA Gives Drug Makers One-Year Reprieve From DSCSA Product Identifier Requirement
Executive Summary
FDA will not take enforcement action against pharmaceutical manufacturers that miss this year’s serialization deadline under DSCSA. Enforcement won't begin until a year later. The serialization requirement is the second wave of a three-part system for tracking and tracing pharmaceutical products through the supply chain to thwart drug counterfeiters.
You may also be interested in...
As Supply Chain Partners Ramp Up For November DSCSA Deadline, US FDA Gives Them Another Year
Potential distribution hitches could spark shortages of legitimate drugs if the system is not fully ready for package-level tracing requirements, US FDA says in delaying enforcement of the program a decade in the making. Poll shows supply chain partners were making significant progress in preparing for the 27 November deadline.
Drug Makers Have Exceeded Expectations In Implementing DSCSA Serialization
A new barcode assessment study finds the US pharmaceutical industry has come a long way in serializing drug products over the past several years.
US FDA Issues Long-Awaited DSCSA Grandfathering Guidance
Pharmaceutical manufacturers finally have some clarity on how and when un-serialized drug products can be grandfathered under DSCSA.